How longevity research can lead to therapies for Alzheimer's disease

The rapamycin story

Arlan Richardson, Veronica Galvan, Ai Ling Lin, Salvatore Oddo

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The discovery that rapamycin increases lifespan in mice and restores/delays many aging phenotypes has led to the speculation that rapamycin has 'anti-aging' properties. The major question discussed in this review is whether a manipulation that has anti-aging properties can alter the onset and/or progression of Alzheimer's disease, a disease in which age is the major risk factor. Rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of Alzheimer's disease (AD-Tg) as well as reduce Aβ and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation. All of these parameters are widely recognized as symptoms central to the development of AD. Furthermore, rapamycin has also been shown to improve memory and reduce anxiety and depression in several other mouse models that show cognitive deficits as well as in 'normal' mice. The current research shows the feasibility of using pharmacological agents that increase lifespan, such as those identified by the National Institute on Aging Intervention Testing Program, to treat Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)51-58
Number of pages8
JournalExperimental Gerontology
Volume68
DOIs
StatePublished - Aug 1 2015

Fingerprint

Sirolimus
Alzheimer Disease
Aging of materials
Research
Cerebrovascular Circulation
National Institute on Aging (U.S.)
Data storage equipment
Memory Disorders
Microglia
Therapeutics
Blood
Agglomeration
Anxiety
Chemical activation
Pharmacology
Depression
Phenotype
Testing

Keywords

  • Alzheimer's disease
  • Behavior
  • Cognition
  • Rapamycin

ASJC Scopus subject areas

  • Aging
  • Biochemistry
  • Cell Biology
  • Endocrinology
  • Genetics
  • Molecular Biology

Cite this

How longevity research can lead to therapies for Alzheimer's disease : The rapamycin story. / Richardson, Arlan; Galvan, Veronica; Lin, Ai Ling; Oddo, Salvatore.

In: Experimental Gerontology, Vol. 68, 01.08.2015, p. 51-58.

Research output: Contribution to journalArticle

Richardson, Arlan ; Galvan, Veronica ; Lin, Ai Ling ; Oddo, Salvatore. / How longevity research can lead to therapies for Alzheimer's disease : The rapamycin story. In: Experimental Gerontology. 2015 ; Vol. 68. pp. 51-58.
@article{fa326f36e5af4523bf67a9552a14070f,
title = "How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story",
abstract = "The discovery that rapamycin increases lifespan in mice and restores/delays many aging phenotypes has led to the speculation that rapamycin has 'anti-aging' properties. The major question discussed in this review is whether a manipulation that has anti-aging properties can alter the onset and/or progression of Alzheimer's disease, a disease in which age is the major risk factor. Rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of Alzheimer's disease (AD-Tg) as well as reduce Aβ and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation. All of these parameters are widely recognized as symptoms central to the development of AD. Furthermore, rapamycin has also been shown to improve memory and reduce anxiety and depression in several other mouse models that show cognitive deficits as well as in 'normal' mice. The current research shows the feasibility of using pharmacological agents that increase lifespan, such as those identified by the National Institute on Aging Intervention Testing Program, to treat Alzheimer's disease.",
keywords = "Alzheimer's disease, Behavior, Cognition, Rapamycin",
author = "Arlan Richardson and Veronica Galvan and Lin, {Ai Ling} and Salvatore Oddo",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.exger.2014.12.002",
language = "English (US)",
volume = "68",
pages = "51--58",
journal = "Experimental Gerontology",
issn = "0531-5565",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - How longevity research can lead to therapies for Alzheimer's disease

T2 - The rapamycin story

AU - Richardson, Arlan

AU - Galvan, Veronica

AU - Lin, Ai Ling

AU - Oddo, Salvatore

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The discovery that rapamycin increases lifespan in mice and restores/delays many aging phenotypes has led to the speculation that rapamycin has 'anti-aging' properties. The major question discussed in this review is whether a manipulation that has anti-aging properties can alter the onset and/or progression of Alzheimer's disease, a disease in which age is the major risk factor. Rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of Alzheimer's disease (AD-Tg) as well as reduce Aβ and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation. All of these parameters are widely recognized as symptoms central to the development of AD. Furthermore, rapamycin has also been shown to improve memory and reduce anxiety and depression in several other mouse models that show cognitive deficits as well as in 'normal' mice. The current research shows the feasibility of using pharmacological agents that increase lifespan, such as those identified by the National Institute on Aging Intervention Testing Program, to treat Alzheimer's disease.

AB - The discovery that rapamycin increases lifespan in mice and restores/delays many aging phenotypes has led to the speculation that rapamycin has 'anti-aging' properties. The major question discussed in this review is whether a manipulation that has anti-aging properties can alter the onset and/or progression of Alzheimer's disease, a disease in which age is the major risk factor. Rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of Alzheimer's disease (AD-Tg) as well as reduce Aβ and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation. All of these parameters are widely recognized as symptoms central to the development of AD. Furthermore, rapamycin has also been shown to improve memory and reduce anxiety and depression in several other mouse models that show cognitive deficits as well as in 'normal' mice. The current research shows the feasibility of using pharmacological agents that increase lifespan, such as those identified by the National Institute on Aging Intervention Testing Program, to treat Alzheimer's disease.

KW - Alzheimer's disease

KW - Behavior

KW - Cognition

KW - Rapamycin

UR - http://www.scopus.com/inward/record.url?scp=84938061050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938061050&partnerID=8YFLogxK

U2 - 10.1016/j.exger.2014.12.002

DO - 10.1016/j.exger.2014.12.002

M3 - Article

VL - 68

SP - 51

EP - 58

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

ER -